Breakthrough Phase 2 survodutide data liver fibrosis MASH Breakthrough Phase 2 survodutide data liver fibrosis MASH Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
